Journal
EXPERT REVIEW OF PROTEOMICS
Volume 11, Issue 2, Pages 227-236Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14789450.2014.897611
Keywords
biomarkers; cancer; diagnosis; glycoproteome; lectins
Categories
Funding
- Science and Technology Program [0068GF]
- National Institute of Health (USA) [R15ES021079-01]
- National Science Foundation (USA) [1334417]
- Directorate For Engineering
- Div Of Civil, Mechanical, & Manufact Inn [1334417] Funding Source: National Science Foundation
Ask authors/readers for more resources
The nine FDA-approved protein biomarkers for the diagnosis and management of cancer are approaching maturity, but their different glycosylation compositions relevant to early diagnosis still remain practically unexplored at the sub-glycoproteome scale. Lectins generally exhibit strong binding to specific sub-glycoproteome components and this property has been quite poorly addressed as the basis for the early diagnosis methods. Here, we discuss some glycoproteome issues that make tackling the glycoproteome particularly challenging in the cancer biomarkers field and include a brief view for next generation technologies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available